Regulators of androgen action resource: A one-stop shop for the comprehensive study of androgen receptor action

Database

Volumn 2016, Issue , 2016, Pages

  Depriest, Adam D ^a   Fiandalo, Michael V ^b   Schlanger, Simon ^c   Heemers, Frederike ^c   Mohler, James L ^b   Liu, Song ^b   Heemers, Hannelore V ^a,c  

^a Department of Cancer Genetics ^*  (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; ISOPROTEIN; LIGAND;

BIOLOGY; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENOMICS; HUMAN; INTERNET; MALE; METABOLISM; PROCEDURES; PROSTATE TUMOR; PROTEIN DATABASE; SIGNAL TRANSDUCTION; SOFTWARE;

ANDROGENS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DATABASES, PROTEIN; GENE EXPRESSION REGULATION; GENOMICS; HUMANS; INTERNET; LIGANDS; MALE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; SOFTWARE;

EID: 84969916284     PISSN: 17580463     EISSN: None     Source Type: Journal    
DOI: 10.1093/database/bav125     Document Type: Article

References (59)

1. Heinlein, C.A., and Chang, C. (2004) Androgen receptor in prostate cancer. Endocr. Rev., 25, 276-308.
2. Heemers, H.V., and Tindall, D.J. (2007) Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev., 28, 778-808.
3. Denmeade, S.R., and Isaacs, J.T. (2002) A history of prostate cancer treatment. Nat. Rev. Cancer, 2, 389-396.
4. Schmidt, L.J., and Tindall, D.J. (2013) Androgen receptor: past, present and future. Curr. Drug Targets, 14, 401-407.
5. Siegel, R., Ma, J., Zou, Z., and Jemal, A. (2014) Cancer statistics, 2014. CA Cancer J. Clin., 64, 9-29.
6. Chang, K.H., Ercole, C.E., and Sharifi, N. (2014) Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences. Br. J. Cancer, 111, 1249-1254.
7. Knudsen, K.E., and Penning, T.M. (2010) Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol. Metab., 21, 315-324.
8. Mills, I.G. (2014) Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat. Rev. Cancer, 14, 187-198.
9. Heemers, H.V. (2014) Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities? Int. J. Biol. Sci., 10, 576-587.
10. Karantanos, T., Evans, C.P., Tombal, B. et al. (2015) Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur. Urol., 67, 470-479.
11. Ryan, C.J., and Tindall, D.J. (2011) Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J. Clin. Oncol., 29, 3651-3658.
12. Penning, T.M. (2014) Androgen biosynthesis in castrationresistant prostate cancer. Endocr. Relat. Cancer, 21, T67-T78.
13. Fiandalo, M.V., Wu, W., and Mohler, J.L. (2013) The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr. Drug Targets, 14, 420-440.
14. Chang, K.H., Li, R., Papari-Zareei, M. et al. (2011) Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.Proc. Natl. Acad. Sci. USA, 108, 13728-13733.
15. Mohler, J.L., Titus, M.A., Bai, S. et al. (2011) Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res., 71, 1486-1496.
16. Stanbrough, M., Bubley, G.J., Ross, K. et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res., 66, 2815-2825.
17. Mostaghel, E.A., Marck, B.T., Plymate, S.R. et al. (2011) Resistance to CYP17A1 inhibition with abiraterone in castration- resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res., 17, 5913-5925.
18. Chen, E.J., Sowalsky, A.G., Gao, S. et al. (2015) Abiraterone treatment in castration-resistant prostate cancer selects forprogesterone responsive mutant androgen receptors. Clin. Cancer Res., 21, 1273-1280.
19. Efstathiou, E., Titus, M., Tsavachidou, D. et al. (2012) Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J. Clin. Oncol., 30, 637-643.
20. Grasso, C.S., Wu, Y.M., Robinson, D.R. et al. (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature, 487, 239-243.
21. Ellem, S.J., and Risbridger, G.P. (2010) Aromatase and regulating the estrogen:androgen ratio in the prostate gland. J. Steroid Biochem. Mol. Biol., 118, 246-251.
22. Sahu, B., Laakso, M., Pihlajamaa, P. et al. (2012) FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res., 73, 1570-1580.
23. Arora, V.K., Schenkein, E., Murali, R. et al. (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell, 155, 1309-1322.
24. Sharifi, N. (2014) Steroid receptors aplenty in prostate cancer. N. Engl. J. Med., 370, 970-971.
25. Heemers, H.V., Regan, K.M., Schmidt, L.J. et al. (2009) Androgen modulation of coregulator expression in prostate cancer cells. Mol. Endocrinol., 23, 572-583.
26. Xu, K., Shimelis, H., Linn, D.E. et al. (2009) Regulation of androgen receptor transcriptional activity and specificity by RNF6- induced ubiquitination. Cancer Cell, 15, 270-282.
27. Ianculescu, I., Wu, D.Y., Siegmund, K.D. et al. (2012) Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells. J. Biol. Chem., 287, 4000-4013.
28. Elbanna, M., and Heemers, H.V. (2014) Alternative approaches to prevent androgen action in prostate cancer: Are we there yet? Discov. Med., 17, 267-274.
29. Heemers, H., and Tindall, D. (2010) In: Figg, W. D., Chau, C. H., and Small, E. (eds). Drug Management of Prostate Cancer. Springer, pp. 41-52.
30. Chmelar, R., Buchanan, G., Need, E.F. et al. (2007) Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer, 120, 719-733.
31. Heemers, H., and Tindall, D. (2005) Androgen receptor coregulatory proteins as potential therapeutic targets in the treatment of prostate cancer. Curr. Cancer Ther. Rev., 1, 175-186.
32. Wang, Y., Lonard, D.M., Yu, Y. et al. (2011) Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol. Endocrinol., 25, 2041-2053.
33. Wang, Y., Lonard, D.M., Yu, Y. et al. (2014) Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res., 74, 1506-1517.
34. Jin, C., Yang, L., Xie, M. et al. (2014) Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. Proc. Natl. Acad. Sci. USA, 111, 9235-9240.
35. Ravindranathan, P., Lee, T.K., Yang, L. et al. (2013) Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat. Commun., 4, 1923.
36. Heemers, H.V., Regan, K.M., Dehm, S.M. et al. (2007) Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: Evidence for a role for serum response factor in prostate cancer. Cancer Res., 67, 10592-10599.
37. Heemers, H.V., Sebo, T.J., Debes, J.D. et al. (2007) Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res., 67, 3422-3430.
38. Agoulnik, I.U., Vaid, A., Nakka, M. et al. (2006) Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res., 66, 10594-10602.
39. Halkidou, K., Gnanapragasam, V.J., Mehta, P.B. et al. (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene, 22, 2466-2477.
40. Belandia, B., Powell, S.M., Garcia-Pedrero, J.M. et al. (2005) Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol. Cell Biol., 25, 1425-1436.
41. Xu, K., Wu, Z.J., Groner, A.C. et al. (2012) EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science, 338, 1465-1469.
42. Wang, Q., Li, W., Zhang, Y. et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 138, 245-256.
43. Sharma, N.L., Massie, C.E., Ramos-Montoya, A. et al. (2013) The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell, 23, 35-47.
44. Yepuru, M., Wu, Z., Kulkarni, A. et al. (2013) Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin. Cancer Res., 19, 5613-5625.
45. Heemers, H.V., Verhoeven, G., and Swinnen, J.V. (2006) Androgen activation of the sterol regulatory element-binding protein pathway: Current insights. Mol. Endocrinol., 20, 2265-2277.
46. Locke, J.A., Guns, E.S., Lubik, A.A. et al. (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res., 68, 6407-6415.
47. Cho, E., Montgomery, R.B., and Mostaghel, E.A. (2014) Minireview: SLCO and ABC transporters: A role for steroid transport in prostate cancer progression. Endocrinology, 155, 4124-4132.
48. Hryb, D.J., Nakhla, A.M., Kahn, S.M. et al. (2002) Sex hormonebinding globulin in the human prostate is locally synthesized and may act as an autocrine/paracrine effector. J. Biol. Chem., 277, 26618-26622.
49. Norris, J.D., Chang, C.Y., Wittmann, B.M. et al. (2009) The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol. Cell, 36, 405-416.
50. He, H.H., Meyer, C.A., Shin, H. et al. (2010) Nucleosome dynamics define transcriptional enhancers. Nat.Genet., 42, 343-347.
51. Marshall, T.W., Link, K.A., Petre-Draviam, C.E. et al. (2003) Differential requirement of SWI/SNF for androgen receptor activity. J. Biol. Chem., 278, 30605-30613.
52. Malovannaya, A., Lanz, R.B., Jung, S.Y. et al. (2011) Analysis of the human endogenous coregulator complexome. Cell, 145, 787-799.
53. Gottlieb, B., Beitel, L.K., Nadarajah, A. et al. (2012) The androgen receptor gene mutations database: 2012 update. Hum. Mutat., 33, 887-894.
54. McKenna, N.J., Cooney, A.J., DeMayo, F.J. et al. (2009) Minireview: Evolution of NURSA, the Nuclear Receptor Signaling Atlas. Mol. Endocrinol., 23, 740-746.
55. Chia, K., O'Brien, M., Brown, M. et al. (2015) Targeting the androgen receptor in breast cancer. Curr. Oncol. Rep., 17, 4.
56. Boorjian, S.A., Heemers, H.V., Frank, I. et al. (2009) Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr. Relat. Cancer, 16, 123-137.
57. Chang, C., Lee, S.O., Yeh, S. et al. (2014) Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene, 33, 3225-3234.
58. Tadokoro-Cuccaro, R., and Hughes, I.A. (2014) Androgen insensitivity syndrome. Curr. Opin. Endocrinol. Diabetes Obes., 21, 499-503.
59. Adachi, M., Takayanagi, R., Tomura, A. et al. (2000) Androgeninsensitivity syndrome as a possible coactivator disease. N. Engl. J. Med., 343, 856-862.